Comments
Optimus Pharma has applied for emergency approval for Phase 3 clinical trial of its generic version of Molnupiravir from the Drugs Controller General of India.
“Phase 2a clinical trial study on enrolled 202 non-hospitalised adults is already made available. Virological analysis was characterized by marked decrease in positive viral culture in subjects who received Molnupiravir (all doses) relative to placebo - at day 5: 0% (0/47) for Molnupiravir and 24 pc (6/25) for placebo,’’ the Hyderabad-based company said in a release.
Furthermore, secondary objective for faster decrease in infectious virus among people with early Covid-19 who were treated with Molnupiravir are encouraging and phase-3 clinical trials were warranted for checking the efficacy of the molecule across demographics, particularly as the SARS-CoV-2 virus, it added.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.